openPR Logo
Press release

BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regeneration

07-01-2021 10:31 AM CET | Health & Medicine

Press release from: BellaSeno GmbH

/ PR Agency: akampion
- Collaboration with Fraunhofer IZI further expanded
- Funding provided by Sächsische Aufbaubank

Leipzig, Germany, July 1, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has initiated a program on tendon and ligament reconstruction funded by the State of Saxony´s Sächsische Aufbaubank (SAB). The program will be run in close collaboration with Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), which will be responsible for the development of an animal model for subsequent in vivo performance testing of the scaffolds.

The goal of the program is to design and evaluate next-generation scaffolds for tendon and ligament reconstruction, incl. assessment of their biomechanical properties and manufacturing processes. The novel scaffolds will be based on BellaSeno´s proprietary Senella® platform, which has already generated promising results in first-in-human trials in breast reconstruction. Senella® scaffolds are made of a biocompatible and absorbable polymer that is FDA-approved and CE-marked for a variety of clinical applications. The scaffolds are designed to slowly get absorbed by the body while the patient's own tissue forms synchronously, resulting in natural tissue with no foreign body remnants.

Human tendons and ligaments are made of complex structures that include blood vessels, nerves and lymphatic vessels. They link bones and muscles and need to have robust biomechanical properties as they are the key connective links of body movements. At present, torn tendons and ligaments are treated with conservative management, surgical intervention, or replacement with autografts.
The global orthopedic soft tissue implant market is projected to reach US $9.4 billion by 2024.

"We believe that our Senella technology is very well suited to address the growing need of tendon and ligament reconstruction," said Dr. Navid Khani, Head of R&D at BellaSeno. “Due to its porous and flexible structures, Senella scaffolds are ideal for seamlessly fitting into the bone and muscle environment. As a first step, we will develop novel porous architectures which can bear the mechanical forces typical for tendon and ligaments.”

"We are delighted about the SAB funding and the further expansion of our good collaboration with Fraunhofer IZI. Most importantly, this program allows us to enter new high growth markets with our Senella resorbable implant technology," said Mohit Chhaya, PhD, CEO of BellaSeno. "Our vision is to step-by-step create a family of scaffolds which can target tendons/ligaments in different regions of the body, e.g., shoulder, hands, or Achilles tendon. As our Senella scaffolds gradually get absorbed by the body, we hope that we can transform the quality of life of patients and athletes in need for tendon or ligament replacements, especially at a young age."

###

Contact BellaSeno
BellaSeno GmbH
Dr. Mohit Chhaya
mohit.chhaya@bellaseno.com
Tel.: +49 176 2283 9583

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

About BellaSeno

BellaSeno GmbH was founded in 2015 and is located on the BioCity campus in Leipzig, Germany. The Company is developing novel absorbable soft tissue reconstruction implants made by additive manufacturing (3D-printing) under ISO 13485 certification. The Company has received substantial financial support from private investors as well as from the Saxony Development Bank (SAB), the European Fund for Regional Development (EFRE) and Germany´s Federal Ministry of Education and Research (BMBF). The Company is thereby co-funded from tax resources based on the budget adopted by the members of Saxon State Parliament.

About Senella®
Senella® is a patented porous scaffold made of absorbable Polycaprolactone (PCL) containing highly specialized topological and design features, which act as recipients for injected fat tissue isolated with a standard liposuction procedure. The implant is designed to get absorbed over a span of two years and to provide a stable platform for the injected fat tissue to mature, adapt to its environment and stabilize. The clinical end result is a natural soft tissue – without remnants of foreign material. Senella® therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release BellaSeno Initiates Scaffold Development Program for Tendon and Ligament Regeneration here

News-ID: 2318527 • Views:

More Releases from BellaSeno GmbH

BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facil …
- Seamless transition from R&D to commercial-scale additive manufacturing - Leading-edge cleanroom, no-touch manufacturing - GMP capabilities for internal and contract manufacturing Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. It is the one
BellaSeno and Charite - Universitaetsmedizin Berlin Collaborate Under BMBF-Funde …
- Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes - BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485 Leipzig, Germany, March 24, 2020 - BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charite - Universitaetsmedizin Berlin under the recently established SyMBoD consortium. Under the agreement, BellaSeno will design and manufacture personalized, 3D-printed, absorbable
Evonik and BellaSeno partner to enable the launch of an innovative 3D printed br …
- 3D printed breast scaffolds to be made of RESOMER® - Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts - Technology designed to improve quality of life for patients after breast reconstruction and augmentation - Human clinical trials to commence later this year Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing

All 5 Releases


More Releases for Senella

BellaSeno Wins Prestigious German Innovation Award 2021
- Leading-edge Senella® soft tissue technology awarded for excellence in B2B / medical technologies Leipzig, Germany, May 18, 2021 – BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that the Company has received the German Innovation Award from the German Design Council for its Senella® technology in the category #W2 Excellence in Business to Business - Medical Technologies. BellaSeno has been chosen among
BellaSeno Establishes GMP-Compliant High-Throughput Additive Manufacturing Facil …
- Seamless transition from R&D to commercial-scale additive manufacturing - Leading-edge cleanroom, no-touch manufacturing - GMP capabilities for internal and contract manufacturing Leipzig, Germany, November 17, 2020 - BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the establishment of a novel, leading-edge additive manufacturing facility for medical implants supported by the Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany. It is the one
Evonik and BellaSeno partner to enable the launch of an innovative 3D printed br …
- 3D printed breast scaffolds to be made of RESOMER® - Degradation of RESOMER® to match the growth of the patient’s own tissue for natural breasts - Technology designed to improve quality of life for patients after breast reconstruction and augmentation - Human clinical trials to commence later this year Evonik, a global leader in biomaterials for implantable medical devices, and BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, today announced the signing
Novel Data on BellaSeno’s Biodegradable Breast Implants to Be Presented by Co- …
- Two presentations at the 50th Annual Conference of the German Society of Plastic, Reconstructive and Aesthetic Surgery (DGPRÄC) - Recent publication in scientific journal Additive Manufacturing Leipzig, Germany, September 19, 2019 - BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technologies, today announced that its co-founder Dietmar W. Hutmacher will introduce BellaSeno’s novel approach for breast reconstruction using 3-D-printed scaffolds during the 50th Annual Conference of the German Society
BellaSeno’s Design and Manufacturing Processes Fully ISO 13485 Certified
- Company transitions from research to manufacturing stage, raises an additional EUR 1 million to conduct clinical trial - Among the first medtech companies worldwide to offer integrated contract manufacturing of additively produced implants under ISO standards Leipzig, Germany, July 15, 2019 - BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology, today announced it obtained full ISO 13485 certification for its design and additive manufacturing processes, ranging from the
BellaSeno Receives RegMedNet Award for Cultivating Excellence
- Leipzig-based start-up prepares for first clinical trial in 2019 Leipzig, Germany, December 06, 2018 - BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology, today announced it was awarded the 2018 Award for Cultivating Excellence by RegMedNet for its innovation, creativity, professionalism and investment in young professionals. BellaSeno won the public vote after five finalists were shortlisted by an expert jury. The award was established in 2017 to